LRRK2 and Parkinson disease: Two exceptions were platelet-derived growth factor (PDGF) and monocyte chemoattractant protein one (MCP1), which were increased by 23% (p = 0.003) (Fig. 1b) and 27% (p = 0.01) (Fig. 1c), respectively, in the LRRK2-PD group.